P < .001). The overall mortality rate was 28.0%. Of the variables examined, the strongest risk factor associated with mortality was hemopneumothorax (OR, 12.49; CI,; P ¼ .03), followed by inferior vena cava injury (OR, 12.05; CI, P ¼ .001; Fig).
Objective: Thoracic outlet syndrome (TOS) results from compression of the neurovascular structures in the thoracic outlet. Decompression provides relief of TOS symptoms, but little is known about long-term function and quality of life (QoL) from a patient's perspective. The purpose of this study was to evaluate surgical and QoL outcomes after surgical decompression of the thoracic outlet using a paraclavicular approach.
Methods: We reviewed our prospectively maintained database of patients who underwent thoracic outlet decompression. Short-term outcomes were assessed by the Derkash classification using contingency table methods, and long-term outcomes including 12-Item Short Form Health Survey QoL were assessed by multiple regression. The 12-Item Short Form Health Survey was scored by published criteria, and scalespecific and aggregate mental and physical health-related QoL scores were computed. Aggregate QoL scores range from 0 (terrible) to 100 (perfect) and, for context, average 50 6 10 in the general population for this age group. Secondary outcomes included mortality, complications, and duration of hospital stay.
Results: Between August 2004 and August 2018, we performed 100 decompression procedures. Median age was 35 years (interquartile range, 24-47 years), and 58 (58%) were female. The mean duration of hospital stay was 4.48 days. The etiology of TOS was venous in 46, arterial in 8, neurogenic in 42, and mixed vascular and neurogenic in 4. Good or excellent Derkash results were reported in 77 (77%) patients (46/54 [85%] of those with vascular TOS vs 31/46 [67%] of those with neurogenic etiology; P < .036). Long-term QoL was obtained in 93 of 100 (93%), with a median duration from surgery of 6.1 (3.3-9.3) years. Patients with neurogenic TOS reported significantly lower aggregate mental health QoL than vascular TOS patients (57 vs 59; P < .016). This effect persisted across the entire duration of follow-up and was unaffected by time out from surgery (regression P for time ¼ .509). In contrast, aggregate physical function QoL was unaffected by neurogenic etiology (P ¼ .303), and all patients improved linearly with time (0.5 scale unit/y; P < .009). There were no deaths or injuries to the long thoracic nerve. Complications included pleural effusion or hemothorax requiring evacuation (n ¼ 6), phrenic nerve palsy (n ¼ 6), and lymph leak (n ¼ 2) treated with tube thoracostomy.
Conclusions: Neurogenic TOS is associated with significantly reduced short-term Derkash score. Patient-reported physical health QoL improves linearly with time from surgery regardless of etiology of TOS, whereas mental health QoL is severely affected in neurogenic TOS, and this effect does not improve over time.
Author Disclosures: Z. Al Rstum: Nothing to disclose; H. Sandhu: Nothing to disclose; C. Miller: Nothing to disclose; N. Saqib: Nothing to disclose; G. Martin: Nothing to disclose; J. Besho: Nothing to disclose; K. Charlton-Ouw: Nothing to disclose; A. Azizzadeh: Nothing to disclose. UA). Overall, CCAB had higher rates of stroke (2.6% vs 1.3%; P ¼ .002) and SDM (7.3% vs 3.5%; P < .001) but similar rates of MI (0.9% vs 1.6%; P ¼ .12) compared with ICEA. In SA, no difference was seen in stroke (1.2% for ICEA vs 1.9% for CCAB; P ¼ .36), MI (1.3% vs 1.4%; P ¼ .95), or SDM (2.9% vs 4.7%; P ¼ .13). In UA, no difference was seen in stroke (1.6% for ICEA vs 2.8% for CCAB; P ¼ .06), but ICEA had higher rates of MI (2.4% vs 0.7%; P ¼ .01) and CCAB had higher rates of SDM (5.5% vs 8.2%; P ¼ .01; Table) After logistic regression in the UA cohort, predictors of MI included ICEA (odds ratio [OR], 2.8; 95% confidence interval [CI], 1.1-7.1; P ¼ .03) and symptomatic status (OR, 2.0; 95% CI, 1.1-3.6; P ¼ .02); symptomatic status also predicted stroke (OR, 1.9; 95% CI, 1.04-3.6; P ¼ .04), but CCAB did not.
Conclusions: In patients with symptomatic CAD, both clinical CAD severity and operative strategy affect outcomes. In SA patients, CCAB does not increase perioperative morbidity. However, CCAB in UA patients prevents MI while not appreciably increasing stroke risk. This suggests that coronary revascularization before or concomitant with CEA should be considered in UA patients but that temporally prioritizing the treatment of one vascular bed over the other is less important in SA patients. Objective: Transcarotid artery revascularization (TCAR) using reversal of flow has been shown to be a safe and effective means of treating carotid artery stenosis. However, no real-world analysis of the cost of using TCAR instead of carotid endarterectomy (CEA) for high-risk carotid stenosis has been performed.
Methods: A retrospective, single-center analysis was performed comparing demographics, complications, and costs for patients with Medicare-defined high-risk characteristics undergoing TCAR vs CEA from January 2014 to June 2017. Direct costs were obtained from the hospital finance department. Costs were adjusted to 2017 dollars and are reported as median values.
Results: There were 44 patients who underwent high-risk CEA and 46 patients who underwent TCAR. There were no significant differences in overall demographics or comorbidities. No difference with respect to symptomatic status (CEA, 36.4%; TCAR, 45.7%; P ¼ .496) or treatment of restenosis (CEA, 11.4%; TCAR, 13%; P ¼ 1.0) was noted. Length of stay was also not different (CEA, 3.4 days; TCAR, 2.9 days; P ¼ .65). The 30-day composite outcome of stroke, myocardial infarction, and death was similar between the groups (CEA, 4.6%; TCAR, 2.2%; P ¼ .612). TCAR had lower surgery time (CEA, 137 minutes vs 83 minutes; P < .001). Overall median hospital stay cost for CEA and TCAR was $5093.62 and $10490.18 (P < .001), respectively. The median operating room cost for CEA ($2705.24) was lower than for TCAR ($8974.65), with most of the cost difference explained by operating room supplies (CEA, $780; TCAR, $6258); P < .001. All other major sources of hospital costs, including intensive care unit, pharmacy, laboratory tests, radiology, room and board, and ancillary costs, were similar between the groups.
Conclusions: Compared with CEA, total direct costs are higher for TCAR, with most related to operating room supply costs. However, based on the 2017 Medicare fee schedule, the higher reimbursement for carotid stenting nearly negates this difference. Additional studies evaluating the financial impact of shorter surgery time as well as clinical outcomes are necessary to evaluate the cost-effectiveness between these two procedures.
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The Role of Duplex Ultrasound in Assessing Arteriovenous Fistula Maturation
Yana Etkin, MD, Sonia Talathi, MD, Amit Rao, MD, Merideth Akerman, Martin Lesser, Gregg Landis, MD. Northwell Health, Lake Success, NY Objective: We examined the utility of postoperative color duplex ultrasound (CDU) in assessing arteriovenous fistula (AVF) maturation and determining the need for balloon-assisted maturation (BAM).
Methods: There were 633 patients who underwent AVF creation at a single institution from 2014 to 2016. Of these, 339 patients had a postoperative CDU assessment, which included vein diameter, volume flow (VF), presence of $50% stenosis at the anastomosis or in the fistula, and stealing branches. Outcome variables examined included functional status of AVFs, CDU findings and timing when CDUs were performed. Fistulas were considered mature when they were successfully cannulated on dialysis.
A generalized linear mixed model was created to analyze duplex ultrasound criteria associated with AVF maturation by comparing CDU findings of AVFs used on hemodialysis with those that thrombosed or needed further intervention. The validity of CDU was analyzed by comparing the findings with corresponding fistulography images.
Results: There were 608 CDUs performed in 339 patients; 408 studies correlated with functional status of AVFs, that is, maturation (n ¼ 174), need for BAM (n ¼ 201), or failure (n ¼ 33). The remaining 200 studies were inconclusive, and subsequent CDUs were performed at a later date. The conclusive studies were performed at a median time of 7.86 weeks postoperatively compared with inconclusive studies performed at 2.14 weeks (P < .001). Univariate analysis was performed to compare CDU findings based on functional status of AVFs. Duplex ultrasound results in AVFs requiring BAM and in those that failed to mature were similar and were combined (Table) . Based on generalized linear mixed model analysis, the probability of AVF maturation increases if the vein diameter is $6 mm (odds ratio [OR] , 38.7), there is no stenosis in the fistula (OR, 35.6), there are no stealing branches (OR, 21.6), and there is a VF $675 mL/min (OR, 5.0).There were 195 fistulography images available for review. Vein diameter, presence of stealing branches, and stenosis in the fistula were compared with CDU findings. Sensitivity, specificity, and accuracy were determined, as follows: vein diameter, 84.3%, 28.6%, 72.3%; fistula stenosis, 59.3%, 78.8%, 69.2%; and stealing branches, 20.7%, 92.7%, 71.3%.
Conclusions: Routine CDU surveillance of AVFs is valid and should be performed 6 to 8 weeks postoperatively to identify and to correct small vein diameters, low VF, flow-limiting stenosis, and stealing branches to help ensure AVF maturation.
Author Disclosures: Y. Etkin: Nothing to disclose; S. Talathi: Nothing to disclose; A. Rao: Nothing to disclose; M. Akerman: Nothing to disclose; M. Lesser: Nothing to disclose; G. Landis: Nothing to disclose. Objective: With unsustainably rising health care spending in the United States, the Centers for Medicare and Medicaid Services (CMS) has in recent years attempted to use reimbursement rates to influence utilization of less expensive care sites for covered patients, such as ambulatory surgery facilities and office-based interventions in lieu of hospital service sites. It has been suggested that cost savings have not been realized because of an increase in procedure numbers performed by physicians with ownership interests in nonhospital facilities. CMS has proposed massive reimbursement changes for 2019 that will reduce access angioplasty reimbursement in the ambulatory surgery center setting by 75.9%, whereas stenting would be increased by 12.1% over current levels. The clinical utility of adjunctive stenting in treating access stenosis remains controversial and highly discretionary. Our group performs such procedures in both a hospital and a nonhospital facility in which we have equity interest. We reviewed the prevalence of stent deployment in patients in 
